STOCK TITAN

Innate Pharma S.A. - $IPHA STOCK NEWS

Welcome to our dedicated page for Innate Pharma S.A. news (Ticker: $IPHA), a resource for investors and traders seeking the latest updates and insights on Innate Pharma S.A. stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Innate Pharma S.A.'s stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Innate Pharma S.A.'s position in the market.

Rhea-AI Summary

Innate Pharma (IPHA) will participate in several upcoming investor conferences. The company will be represented by senior executives including CEO Hervé Brailly, EVP Sonia Quaratino, COO Yannis Morel, and President of US Operations Arvind Sood. The schedule includes:

Jefferies Global Healthcare Conference on June 5-6, 2024, in New York.

Goldman Sachs 45th Annual Global Healthcare Conference on June 10-13, 2024, in Miami.

H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference on June 25, 2024.

Stifel 2nd European Healthcare Summit on June 25-27, 2024, in Lyon.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.25%
Tags
conferences
-
Rhea-AI Summary

Innate Pharma announced that five abstracts featuring its drug candidates have been accepted for presentation at the ASCO 2024 Annual Meeting, scheduled for May 31-June 4, 2024, in Chicago. Highlights include:

- Topline results of the TELLOMAK Phase 2 trial for lacutamab in mycosis fungoides, confirming promising clinical activity.

- Two posters on IPH6501, the second-generation ANKET® for CD20-expressing B-cell Non-Hodgkin's Lymphoma, presenting safety, tolerability, and preliminary antineoplastic activity.

- AstraZeneca's updated results for monalizumab in the Phase 2 COAST trial for stage III unresectable NSCLC.

- A poster on the Phase 2 MOZART trial of monalizumab combined with durvalumab and chemotherapy for the first-line treatment of extensive-stage small cell lung cancer.

These presentations underscore Innate Pharma’s commitment to advancing cancer immunotherapy.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.98%
Tags
none
-
Rhea-AI Summary

Innate Pharma announced the results of its 2024 Annual General Meeting (AGM) held on May 23, 2024, in Marseille. The meeting had a quorum of 44.92% with 84 votes cast out of 36,317,268 shares, translating to 36,798,714 voting rights. All resolutions were passed, including the re-election of two Supervisory Board members. Detailed results, resolutions, and the AGM recording are available on the company's website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.98%
Tags
none
Rhea-AI Summary

Innate Pharma, listed on Euronext Paris (IPH) and Nasdaq (IPHA), clarified that their molecule SAR443579/IPH6101 was incorrectly mentioned as having breakthrough designation in an abstract published for the European Hematology Association 2024 Congress. The correct status is that the molecule has received US FDA Fast Track Designation, as communicated in June 2023. This clarification aims to rectify the misinformation released on May 14, 2024, by Sanofi.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.75%
Tags
none
-
Rhea-AI Summary

Innate Pharma announced that four of its drug candidate abstracts have been accepted for presentation at the EHA 2024 Congress in Madrid, from June 13-16, 2024. Two abstracts focus on SAR443579 (IPH6101), an anti-CD123 NK cell engager developed with Sanofi, being tested in a Phase 1/2 trial for blood cancers. The other two abstracts highlight IPH6501, aimed at treating relapsed or refractory CD20-expressing B-cell Non-Hodgkin's Lymphoma, also in Phase 1/2 trials. Chief Medical Officer Dr. Sonia Quaratino underscored the potential benefits of these NK cell engagers for patients with high unmet medical needs.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.06%
Tags
none
-
Rhea-AI Summary

Innate Pharma (NASDAQ: IPHA) released its Q1 2024 business update, highlighting key developments in its clinical pipeline and financial performance. The company presented preclinical data for IPH45, an anti-Nectin-4 ADC, at AACR 2024 and advanced IPH6501, its second-generation ANKET®, into clinical development for NHL. Partner Sanofi progressed SAR443579/IPH6101 to Phase 2 in blood cancers. For Q1 2024, Innate reported revenues of €6.6 million, down from €26 million in Q1 2023. The company's cash position stood at €113.9 million as of March 31, 2024, excluding a pending €4 million milestone payment from Sanofi. Innate anticipates a cash runway until the end of 2025. Multiple presentations at ASCO 2024, including results from the TELLOMAK Phase 2 trial for lacutamab, are scheduled. The FDA lifted a partial clinical hold on lacutamab's IND in January 2024. A conference call to discuss these results will be held today.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.15%
Tags
Rhea-AI Summary

Innate Pharma SA has scheduled a conference call and webcast on May 14, 2024, to discuss the business progress during the first quarter of 2024. Key executives will provide updates on the company's performance and future plans.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.21%
Tags
-
Rhea-AI Summary
Innate Pharma will hold its Annual General Meeting of Shareholders on May 23, 2024, at its headquarters in Marseille, France. The meeting will include the agenda, proposed resolutions, and instructions for participation and voting. Shareholders must register their shares in advance to participate, with additional details available on the company's website. A guided tour of the company's laboratories will also be offered to shareholders on the same day.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.42%
Tags
none
-
Rhea-AI Summary
Innate Pharma announced the advancement of Sanofi-developed NK cell engager SAR443579 / IPH6101 to Phase 2 for blood cancer patients. The first patient was dosed in the Phase 2 dose expansion part of the Sanofi-sponsored clinical trial, triggering a €4m milestone payment to Innate. SAR443579 is being evaluated as a monotherapy for blood cancers with high unmet needs, including R/R AML, B-cell acute lymphoblastic leukemia, and high-risk myelodysplasia. The drug received FDA Fast Track Designation for the treatment of acute myeloid leukemia.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.42%
Tags
Rhea-AI Summary
Innate Pharma SA announces promising preclinical data for IPH45, a novel exatecan-Antibody Drug Conjugate targeting Nectin-4, showing stronger activity than EV in urothelial tumors. IPH45 demonstrates anti-tumor efficacy in various solid tumors and EV-refractory models, with plans for IND in 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.08%
Tags
none
Innate Pharma S.A.

Nasdaq:IPHA

IPHA Rankings

IPHA Stock Data

235.13M
30.66M
0.11%
0.1%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
Marseille

About IPHA

innate pharma s.a. is a clinical-stage biotechnology company dedicated to improving cancer treatment and clinical outcomes for patients through first-in-class therapeutic antibodies that harness the innate immune system. innate pharma specializes in immuno-oncology, a new therapeutic field that is changing cancer treatment by mobilizing the power of the body’s immune system to recognize and kill cancer cells. the company's broad pipeline includes four first-in-class clinical stage antibodies as well as preclinical candidates and technologies that have the potential to address a broad range of cancer indications with high unmet medical needs. innate pharma has pioneered the discovery and development of checkpoint inhibitors, with a unique expertise and understanding of natural killer cell biology. this innovative approach has resulted in major alliances with leaders in the biopharmaceutical industry including astrazeneca, bristol-myers squibb, novo nordisk a/s and sanofi. innate pharma